Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies.

ABSTRACT: The widespread outbreak of the monkeypox virus (MPXV) recognized in 2022 poses new challenges for public healthcare systems worldwide. With more than 86,000 people infected, there is concern that MPXV may become endemic outside of its original geographical area leading to repeated human spillover infections or continue to be spread person-to-person. Fortunately, classical public health measures (e.g., isolation, contact tracing and quarantine) and vaccination have blunted the spread of the virus, but cases are continuing to be reported in 28 countries in March 2023. We describe here the vaccines and drugs available for the prevention and treatment of MPXV infections. However, although their efficacy against monkeypox (mpox) has been established in animal models, little is known about their

SUBMITTER: Roper RL 

PROVIDER: S-EPMC10120921 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature